EMFLAZA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emflaza, and when can generic versions of Emflaza launch?
Emflaza is a drug marketed by Ptc Therap and is included in two NDAs.
The generic ingredient in EMFLAZA is deflazacort. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the deflazacort profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emflaza
A generic version of EMFLAZA was approved as deflazacort by AUROBINDO PHARMA LTD on February 9th, 2024.
Summary for EMFLAZA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 2 |
Patent Applications: | 6,337 |
Drug Prices: | Drug price information for EMFLAZA |
What excipients (inactive ingredients) are in EMFLAZA? | EMFLAZA excipients list |
DailyMed Link: | EMFLAZA at DailyMed |
Recent Clinical Trials for EMFLAZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
PTC Therapeutics | Phase 3 |
Pharmacology for EMFLAZA
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for EMFLAZA
US Patents and Regulatory Information for EMFLAZA
EMFLAZA is protected by zero US patents and two FDA Regulatory Exclusivities.
FDA Regulatory Exclusivity protecting EMFLAZA
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷ Try a Trial
TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-003 | Feb 9, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-001 | Feb 9, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-003 | Feb 9, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |